Latebreakers: ADHD drug given Schedule II classification

May 21, 2007

Prodrug stimulant lisdexamfetamine dimesylate (Vyvanse, Shire) will be considered a Schedule II substance, according to recent word from DEA.

Prodrug stimulant lisdexamfetamine dimesylate (Vyvanse, Shire) will be considered a Schedule II substance, according to recent word from DEA. This marks the final step in the approval process for the drug, which is expected to launch in the second quarter of this year. Vyvanse was approved by the FDA in February for the treatment of ADHD and is thought to have a lower abuse potential than existing stimulants used to treat the disorder.